Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said its new drug application (NDA) for its cancer drug was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China based on the positive results from the pivotal phase III, according to a Thursday filing with the Hong Kong bourse.
Sacituzumab Tirumotecan treats adult patients with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression after treatment with EGFR-tyrosine kinase inhibitor (TKI) therapy, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments